PFE - Pfizer Inc.

NYSE - NYSE Delayed price. Currency in USD
35.64
-0.07 (-0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close35.71
Open35.61
Bid35.43 x 1000
Ask0.00 x 800
Day's range35.43 - 35.75
52-week range31.67 - 39.43
Volume14,928,519
Avg. volume22,173,674
Market cap208.479B
Beta0.95
PE ratio (TTM)9.90
EPS (TTM)3.60
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yield1.36 (3.83%)
Ex-dividend date2018-05-10
1y target est39.70
Trade prices are not sourced from all markets
  • Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
    Zacks2 days ago

    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

  • Eli Lilly’s Valuation on May 17
    Market Realist2 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks2 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist2 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist2 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist2 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Business Wire3 days ago

    Invacare Corporation Appoints Petra Danielsohn-Weil, PhD, to Board of Directors

    Invacare Corporation (NYSE: IVC) today announced the appointment of Petra Danielsohn-Weil, PhD, to its Board of Directors, effective May 17, 2018. From 2014 until her retirement in August 2017, Ms. Danielsohn-Weil was the Regional President for Pfizer Essential Health - Europe, a leader in non-viral anti-infectives, biosimilars and sterile injectable medicines and a unit of Pfizer Inc. (NYSE:PFE), a research-based, global biopharmaceutical company.

  • Business Wire3 days ago

    Invacare Corporation Appoints Petra Danielsohn-Weil, PhD, to Board of Directors

    Invacare Corporation (IVC) today announced the appointment of Petra Danielsohn-Weil, PhD, to its Board of Directors, effective May 17, 2018. From 2014 until her retirement in August 2017, Ms. Danielsohn-Weil was the Regional President for Pfizer Essential Health - Europe, a leader in non-viral anti-infectives, biosimilars and sterile injectable medicines and a unit of Pfizer Inc. (PFE), a research-based, global biopharmaceutical company.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist3 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • Sangamo Therapeutics Stock History
    Motley Fool3 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist3 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist3 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks3 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
    Zacks3 days ago

    Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

    European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist3 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • Why Exelixis Stock Fell Last Week
    Market Realist3 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Business Wire3 days ago

    LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

    Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

  • Teva’s Fiscal Guidance: Confidence in Its Growth
    Market Realist3 days ago

    Teva’s Fiscal Guidance: Confidence in Its Growth

    Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.

  • Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
    Motley Fool3 days ago

    Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?

    Good news for Pfizer muddies the waters somewhat for Alnylam's outlook.

  • 5 Companies To Watch As Marijuana Legalization Approaches
    Oilprice.com4 days ago

    5 Companies To Watch As Marijuana Legalization Approaches

    Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains

  • Business Wire4 days ago

    Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO

    Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 1-5, 2018.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist4 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
    Zacks4 days ago

    Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

    Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

  • Business Wire5 days ago

    Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

    Pfizer Inc. (PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S. “As the first approved epoetin alfa biosimilar in the U.S., RETACRIT may provide patients and their physicians with increased access to a high-quality, lower-cost alternative treatment option for anemia and the reduction of allogeneic red blood cell (RBC) transfusions in certain patients,” said Berk Gurdogan, U.S. Institutions President, Pfizer Essential Health.

  • Pfizer's biosimilar of anemia treatments gets FDA nod
    Business Insider UK5 days ago

    Pfizer's biosimilar of anemia treatments gets FDA nod

    The approval comes one year after the U.S. Food and Drug Administration rejected the drug, Retacrit, a copy of Amgen's Epogen and Johnson & Johnson's Procrit, as a treatment for a drop in red blood cells caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV. The biosimilar was also approved for use before and after surgery to safeguard against the need for red blood cell transfusions due to blood loss from surgery.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes